SecBot SecBot
SECBOTREPLAY Home › Report › FULC

FULC · HbF asset sale $7M

Fulcrum Therapeutics, Inc. · 425 filed Nov 12, 2026 at 16:11 ET

At the news

NEUTRALIMPACT 3/10

425 filed Nov 12, 2026 at 16:11 ET

Fulcrum Therapeutics entered into an asset purchase agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third party for approximately $7.0 million in cash. The sale is contingent on the closing of Fulcrum's pending merger with Slate Medicines (or, if the merger is terminated, upon receipt of necessary approvals). Proceeds will be placed into escrow and credited to Fulcrum's net cash, increasing the expected cash dividend to Fulcrum stockholders in connection with the merger.

  • Fulcrum and Slate entered into an asset purchase agreement on November 7, 2026 for Fulcrum's early-stage HbF assets.
  • Sale price is approximately $7.0 million in cash.
  • Closing is contingent on consummation of the Fulcrum-Slate merger (Merger Agreement dated August 16, 2026) or, if merger is terminated, upon receipt of necessary approvals.
  • Proceeds will be funded into escrow before the merger closes and credited to Fulcrum's net cash, increasing the expected cash dividend to Fulcrum stockholders.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access